SCHEMBL2048102

SCHEMBL2048102

Oc1ccc(F)cc1CNc1cncc(Br)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.50
MEN1 O00255 7/20 0.50
MAPT P10636 4/20 0.45
ALDH1A1 P00352 4/20 0.45
POLB P06746 1/20 0.45
PLEC Q15149 1/20 0.45
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
EGFR P00533 1/20 0.42
PKM P14618 3/20 0.41
HPGD P15428 2/20 0.41
HTT P42858 2/20 0.41
APP P05067 1/20 0.40
KDM4E B2RXH2 4/20 0.40
LMNA P02545 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2043884 0.90 MEN1 (0.46) KMT2AMEN1MAPTALDH1A1POLB
SCHEMBL2040520 0.83 MEN1 (0.60) KMT2AMEN1MAPTALDH1A1POLB
SCHEMBL2036868 0.81 MAPT (0.59) KMT2AMEN1MAPTALDH1A1CA12
SCHEMBL2042119 0.81 MEN1 (0.45) KMT2AMEN1MAPTALDH1A1POLB
SCHEMBL22191439 0.78 KDM4E (0.46) ALDH1A1HPGDKDM4ELMNAKCNH2
SCHEMBL2035328 0.77 MEN1 (0.36) KMT2AMEN1MAPTALDH1A1POLB
SCHEMBL22191674 0.75 L3MBTL1 (0.53) KMT2AMEN1MAPTALDH1A1POLB
SCHEMBL2038199 0.75 KDM4E (0.46) KMT2AMEN1MAPTALDH1A1POLB
SCHEMBL6122773 0.74 CCNT1 (0.49) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL20376006 0.74 MAOB (0.56) KMT2AMEN1MAPTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2516399-B1 PHENOLIC DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RES & DEV (FR) 2018-04-18 EP claimed
US-9120753-B2 Phenol derivatives and pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2015-09-01 US claimed
US-20130172564-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-07-04 US claimed
EP-2516399-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF Galderma Research & Development (FR) 2012-10-31 EP claimed
WO-2011077044-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-30 WO claimed
EP-2516399-B1 PHENOLIC DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RES & DEV (FR) 2018-04-18 EP disclosed
US-9120753-B2 Phenol derivatives and pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2015-09-01 US disclosed
US-20130172564-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-07-04 US disclosed
EP-2516399-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF Galderma Research & Development (FR) 2012-10-31 EP disclosed
WO-2011077044-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172564-A1 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF TYR, MITF, CUTA KMT2A 2426/4885MEN1 3023/4885MAPT 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.